HERCULES, CA--(Marketwired - July 29, 2013) - Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, today announced the launch of its QX200 Droplet Digital™ PCR (ddPCR) system, the second generation of the company's Droplet Digital™ PCR technology.
The QX200 system is the only digital PCR system that works with EvaGreen and TaqMan hydrolysis probes (reagents that are used with the instrument) to provide users more flexibility in the design of their digital PCR experiments. The new system can be used with the company's recently launched 75 Droplet Digital PCR-validated assays (tests) for cancer mutation detection and genomic variations (gene copy number) to make running an experiment easier. Digital PCR provides researchers a tool for the detection of rare mutations (including distinguishing rare sequences in tumors), precise measurement of copy number variation, and absolute quantification of gene expression.
"Droplet Digital PCR has been widely embraced, demonstrating a level of sensitivity and simplicity not available by any other means," said Brad Crutchfield, Bio-Rad President, Life Science Group. "The launch of the QX200 system and ddPCR validated assays demonstrates Bio-Rad's commitment to innovation and leadership in this exciting technology."
Researchers in institutions worldwide are using the ddPCR system to conduct groundbreaking research on HIV, cancer, and disease characterization, resulting in more than 30 peer-reviewed publications in the less than two years since Bio-Rad brought ddPCR to the market. Using ddPCR, HIV researchers at the University of California, San Diego were able to demonstrate that an infant born with HIV was functionally cured. Other researchers have shown the technology's promise in screening for cancer and diagnosing infectious disease as well as in quantifying genetically modified organisms in food and monitoring water quality.
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) has been at the center of scientific discovery for 60 years, manufacturing and distributing a broad range of products for life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and industry customers through its global network of operations. The company employs approximately 7,300 people worldwide and had revenues exceeding $2 billion in 2012. Visit us at www.bio-rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.